Esperion Therapeutics, Inc. (ESPR) Position Maintained by Legal & General Group Plc

Legal & General Group Plc held its stake in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 4,054 shares of the biopharmaceutical company’s stock at the end of the 2nd quarter. Legal & General Group Plc’s holdings in Esperion Therapeutics were worth $192,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in ESPR. Teachers Advisors LLC boosted its position in shares of Esperion Therapeutics by 56.7% during the 4th quarter. Teachers Advisors LLC now owns 33,502 shares of the biopharmaceutical company’s stock valued at $419,000 after purchasing an additional 12,122 shares in the last quarter. Russell Investments Group Ltd. bought a new stake in shares of Esperion Therapeutics during the 1st quarter valued at about $961,000. Wells Fargo & Company MN boosted its position in shares of Esperion Therapeutics by 39.4% during the 1st quarter. Wells Fargo & Company MN now owns 11,602 shares of the biopharmaceutical company’s stock valued at $410,000 after purchasing an additional 3,282 shares in the last quarter. State Board of Administration of Florida Retirement System bought a new stake in shares of Esperion Therapeutics during the 1st quarter valued at about $316,000. Finally, First Trust Advisors LP bought a new stake in shares of Esperion Therapeutics during the 1st quarter valued at about $713,000. Institutional investors own 83.30% of the company’s stock.

Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.92) EPS for the quarter, missing analysts’ consensus estimates of ($1.67) by ($0.25). During the same period in the previous year, the company earned ($0.62) earnings per share.

ESPR has been the topic of several research analyst reports. Jefferies Group LLC initiated coverage on Esperion Therapeutics in a research report on Monday, July 10th. They set a “hold” rating and a $55.00 target price on the stock. Stifel Nicolaus restated a “buy” rating and set a $60.00 target price (up previously from $45.00) on shares of Esperion Therapeutics in a research report on Monday, June 26th. UBS AG restated a “buy” rating and set a $57.00 target price (up previously from $52.00) on shares of Esperion Therapeutics in a research report on Tuesday, June 27th. Northland Securities initiated coverage on Esperion Therapeutics in a research report on Tuesday, August 29th. They set an “outperform” rating and a $72.00 target price on the stock. Finally, Citigroup Inc. restated a “buy” rating on shares of Esperion Therapeutics in a research report on Thursday, June 22nd. Seven investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $55.35.

WARNING: This piece of content was originally published by Community Financial News and is the property of of Community Financial News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of US and international copyright law. The correct version of this piece of content can be viewed at https://www.com-unik.info/2017/10/13/esperion-therapeutics-inc-espr-position-maintained-by-legal-general-group-plc.html.

About Esperion Therapeutics

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Want to see what other hedge funds are holding ESPR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Esperion Therapeutics, Inc. (NASDAQ:ESPR).

Institutional Ownership by Quarter for Esperion Therapeutics (NASDAQ:ESPR)

What are top analysts saying about Esperion Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Esperion Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit